Drug Profile
Darbepoetin alfa - Kyowa Kirin/Amgen
Alternative Names: Aranesp; Darbepoetin-α; KRN-321; Nesp; Nespo; Novel erythropoiesis stimulating proteinLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kirin-Amgen
- Developer Amgen; Kirin-Amgen; Kyowa Kirin
- Class Antianaemics; Antineoplastics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anaemia
- Phase III Breast cancer
Most Recent Events
- 15 Mar 2021 Darbepoetin alfa licensed to Clinigen for distribution in Africa and Asia
- 30 Sep 2019 Registered for Anaemia (in patients with chronic renal failure) in Indonesia (SC)
- 19 Oct 2018 Efficacy data from a phase III trial in Anaemia (Chemotherapy-induced, in patients with non-small cell cancer) presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)